- Conditions
- Sarcoma
- Interventions
- dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 1,253
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Yohimbine
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer
- Interventions
- dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, vincristine sulfate, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Aging
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- University of California, Berkeley
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Major Depressive Disorder, Anhedonia
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 13
- States / cities
- West Palm Beach, Florida • Chicago, Illinois • Charlotte, North Carolina + 10 more
- Conditions
- Post-Traumatic Headache
- Interventions
- Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Hodgkin Disease
- Interventions
- Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Cincinnati, Ohio
- Conditions
- Migraine Disorders, Headache, Migraine, Migraine, Migraine Headache, Migraine With Aura, Migraine Without Aura, Headache Disorders, Primary
- Interventions
- Triptan, Doxycycline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Migraine Headache
- Interventions
- Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
- Drug · Behavioral
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Athens, Ohio • Westerville, Ohio
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 55
- States / cities
- Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Psilocybin, Inactive Placebo, Supportive therapy sessions
- Drug · Other · Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Functional Magnetic Resonance Imaging, Interview, Psilocybine, Psychotherapy, Questionnaire Administration
- Procedure · Other · Drug + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Alcohol Use Disorder
- Interventions
- Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
- Drug
- Lead sponsor
- Keith Heinzerling
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
- Interventions
- Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 9
- States / cities
- Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Clofarabine incorporated into a 5-drug regimen
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee • Houston, Texas
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Sheppard Pratt Health System
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Baltimore, Maryland
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Interventions
- Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo)
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Metastatic Melanoma
- Interventions
- vinblastine, Cyclophosphamide, dacarbazine
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Non - Small Cell Lung Cancer NSCLC
- Interventions
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 33
- States / cities
- Chandler, Arizona • Anaheim, California • Duarte, California + 29 more